Notably, the expression of ENTPD1 in ATC was higher than that in normal tissues, suggesting its significance in regulating metabolic pathway and acting important roles in thyroid cancer [43, 44]; LY96 was highly associated with increased intratumoral lymphocytic infiltration in oncocytic PDTC [45]; CASP1 was identified as the most promising biomarker for the diagnosis or treatment of PTC and involved in molecular changes in brain metastatic PTC [46, 47]; patients with low PDIA3 expression had lower etiological specific survival than those with high PDIA3 expression in PTC [48]. This evidence concerns the gene LY96 and thyroid gland carcinoma.